DuPont[™] Vamac[®] An Alternate Accelerator for Vamac[®] Terpolymers: Vulcofac[®] ACT 55

Technical Information — Rev. 2, July 2010

Introduction

DOTG (di-ortho-tolyl guanidine) is an accelerator used in sulfur-cured elastomers like natural rubber, SBR and NBR. It is also used in the curing system of ACM and AEM elastomers containing an acidic cure site and in certain EPDM compounds.

DuPont[™] Vulcofac[®] ACT 55 (tertiary amine complex) is an accelerator developed and commercialized by Safic-Alcan in 2006 as an alternative to guanidine accelerators like DOTG. Please read and understand the MSDS before handling and use of Vulcofac[®] ACT 55.

This study compares the properties obtained with Vulcofac[®] ACT 55 in Vamac[®] ethylene acrylic elastomer terpolymer compounds with compounds cured with a combination of a primary diamine as curing agent and a guanidine as accelerator.

The two guanidine accelerators considered in this study are:

DOTG (=di-ortho-tolyl guanidine) providing good compression set and high modulus

DPG (=diphenyl guanidine) providing good flex fatigue resistance

For handling precautions, processing and safety information, please refer to the "Safe Handling and Processing of Vamac[®] and Vamac[®] Compounds" available from <u>www.vamac.dupont.com</u>.

Formulation

A design of experiment was conducted to evaluate the impact of Vulcofac[®] ACT 55 in a Vamac[®] G recipe. Eighteen Vamac[®] compounds using Vulcofac[®] ACT 55 were tested in this study (see *Table 1*). In parallel, three standard Vamac[®] G recipes using DOTG and/or DPG were selected as a reference for seals and hoses made from Vamac[®] compounds. All Vamac[®] compounds were mixed in the same conditions (full cooling, load factor = 70%, rotor speed = 40 rpm, mixing time = 180 seconds and dumping temperature = 85 °C) using a 1.6 L Francis Shaw Intermeshing internal mixer. All ingredients, except for curatives, were charged using an upside-down mixing technique.



| Control Compounds | 1 | 2 | 3 | Vulcofac [®] ACT 55 Variations |
|--|---------|---------|---------|--|
| | 2 runs | 1 run | 1 run | |
| DuPont [™] Vamac [®] G | 100 phr | 100 phr | 100 phr | 100 phr |
| Naugard [®] 445 | 2 | 2 | 2 | 2 |
| Sterling SO N-550 | 60 | 60 | 60 | 60 |
| Vanfre [®] VAM | 1 | 1 | 1 | 1 |
| Rhenosin [®] W759 | 10 | 10 | 10 | 10 |
| Stearic Acid | 1.5 | 1.5 | 1.5 | 0 and 1.5 phr |
| Armeen [®] 18 D | 0.5 | 0.5 | 0.5 | 0, 0.075 and 1.5 phr |
| Diak [™] No. 1 | 1.5 | 1.25 | 1.25 | 1, 1.5 and 2 phr |
| Ekaland DOTG/C 100% | 4 | 2 | | · |
| Rhenogram DPG 80% | | 2 | 4 | 0, 0.5 and 1 phr Salicylic Acic 0, 2 and 4 ph Vulcofac [®] ACT 5 |

Table 1. DOE (Design of Experiment) with DuPont[™] Vulcofac[®] ACT 55

Rheological Properties

A. Mooney Viscometer Results


The three "control compounds" have similar viscosity and scorch behavior (see Table 2).

| Table 2. Control Compounds - | - Mooney Viscometer Results |
|------------------------------|-----------------------------|
|------------------------------|-----------------------------|

| | Control 1 (DOTG) | Control 2 (DOTG/DPG) | Control 3 (DPG) | 2 phr Vulcofac [®] ACT 55 |
|--------------------------|---------------------|-------------------------|--------------------|---------------------------------------|
| ML (1+4) at 100 °C, (MU) | 34.1 | 33.8 | 33.6 | 37.1 |
| MS at 121 °C, t2, min | 6.3 | 6.1 | 6.2 | 5.4 |
| MS at 121 °C, t5, min | 8.9 | 8.5 | 8.6 | 7.7 |

All Vamac[®] compounds that contain Vulcofac[®] ACT 55 are scorchier and therefore higher in Mooney than "control compounds" using DOTG and/or DPG according to the results presented in *Figure 1*. Vamac[®] recipes using Vulcofac[®] ACT 55 should be corrected by adding more retarding agent like Armeen[®] 18D or Salicylic Acid in order to reach a scorch similar to DOTG or DPG.

Figure 1. DOE with Vulcofac[®] ACT 55 — Mooney Viscosity Results



B. Moving Die Rheometer Results

All compounds were tested in the same conditions using MDR equipment (conditions: $0.5^{\circ}/12$ min at 180 °C). "Control 1" compound (1.5 phr DiakTM 1 + 4 phr DOTG), a standard recipe used for seals and gaskets, clearly has a higher crosslink density (higher MH) and higher cure rate (higher peak rate) than the 2 other Vamac[®] compounds: "Control 2" (= 1.25 phr DiakTM 1 + 2 phr DOTG/2 phr DPG) and "Control 3" (= 1.25 DiakTM 1 + 4 phr DPG) have been considered for hose applications (see *Table 3*).

| | Control 1 (DOTG) | Control 2 (DOTG/DPG) | Control 3 (DPG) | 2 phr Vulcofac [®] ACT 55 |
|--------------------|---------------------|-------------------------|--------------------|---------------------------------------|
| ML, dNm | 0.35 | 0.37 | 0.37 | 0.44 |
| MH, dNm | 12.30 | 9.17 | 7.66 | 10.97 |
| Tc50, min | 1.96 | 1.63 | 1.51 | 2.12 |
| Tc90, min | 5.37 | 5.06 | 4.51 | 6.48 |
| Peak rate, dNm/min | 4.3 | 3 | 3.4 | 4.1 |

Table 3. Control Compounds — MDR Results

Vulcofac[®] ACT 55 is similar to DOTG in cure kinetics of Vamac[®] compounds as can be seen in Figure 2. Vulcofac[®] ACT 55 should cure slightly slower than DOTG.




Figure 2. DOE with Vulcofac[®] ACT 55 — Moving Die Rheometer results

A. Mechanical Properties


Vamac[®] slabs were molded by compression during 5 min at 180 °C and post-cured 4 h at 175 °C in an air circulating oven. Test specimens were die-cut from slabs.

Vulcofac[®] ACT 55 seems to bring about a higher hardness level and lower elongation than DOTG in Vamac[®] compounds when comparing *Table 4* and *Figure 3*.

Table 4. Control Compounds — Mechanical Properties

| | Control 1 (DOTG) | Control 2 (DOTG/DPG) | Control 3 (DPG) | 2 phr Vulcofac [®] ACT 55 |
|------------------------------------|---------------------|-------------------------|--------------------|---------------------------------------|
| Hardness, Shore A, 1 sec | 69.8 | 69.3 | 68.3 | 72.2 |
| Modulus 100%, MPa | 4.8 | 4 | 4.1 | 5.7 |
| Tensile Strength, MPa | 15.6 | 14.8 | 13.9 | 14.6 |
| Elongation, % | 325 | 369 | 328 | 281 |
| Tear Crescent Die C. Fmax, dNm/min | 26.8 | 28.2 | 29.0 | 23.6 |

Figure 3. DOE with Vulcofac[®] ACT 55 — Mechanical properties



B. Compression Set

There are several test procedures commonly used to measure compression set. The standard test is ASTM D395 (VDA 675 216A or ISO815) which requires samples to be removed from the clamps immediately after removal from the oven. Alternatively, procedures VDA 675 216B (often applied for Daimler Chrysler parts) and VDA 675 218 (identical to Volkswagen specification PV 3307) ask for measurement of compression set after cooling the test pieces within the clamps. As a result these tests give significantly higher compression set values as shown in *Table 5*.

Table 5. Control Compounds — Compression Set

| | Control 1 (DOTG) | Control 2 (DOTG/DPG) | Control 3 (DPG) | 2 phr Vulcofac [®] ACT 55 |
|---|---------------------|-------------------------|--------------------|---------------------------------------|
| ASTM D395, 70 h at 150 °C, 6 mm molded pipe | s 19% | 23% | 28% | 24% |
| ASTM D395, 70 h at 150 °C, VDA 67521B | | | | |
| 2 h cooled in clamps, 6 mm molded pips | 27% | 34% | 42% | 30% |
| VW PV 3307, 94 h at 150 °C, 2 mm disks | 58% | 58% | 77% | 61% |
| VW PV 3307, 22 h at 175 °C, 2 mm disks | 59% | 62% | 77% | 58% |

Figure 4 shows that Vulcofac[®] ACT 55 has compression set performance comparable to DOTG (see *Table 5*) so the sealing force should be similar for both DOTG and Vulcofac[®] ACT 55 compounds.




Figure 4. DOE with Vulcofac[®] ACT 55 — Compression Set

Vulcofac[®] ACT 55 can be used as an accelerator in combination with a primary diamine to cure DuPont[™] Vamac[®] terpolymers. Nevertheless, some compound adjustments are necessary to meet properties of existing Vamac[®] compounds based on DOTG.

| Material | Composition | Supplier |
|-----------------------------------|---------------------------------|----------------------|
| Polymer | | |
| Vamac [®] G | Ethylene Acrylic Elastomer | DuPont |
| Release Aids | | |
| Armeen [®] 18D | Octadecyl Amine | Akzo Nobel |
| Ofalub SEO | Complex Organic phosphate ester | Safic-Alcan |
| Vanfre [®] VAM | Complex Organic phosphate ester | R.T. Vanderbilt |
| Stearic Acid | Stearic Acid | Sigma Aldrich Chemie |
| Antioxidants | | |
| Naugard [®] 445 | Diphenyl Amine | Uniroyal Chemical |
| Plasticizers | | |
| Rhenosin [®] W759 | Mixed Ether/Ester Plasticizer | Rhein Chemie |
| Nycoflex [®] ADB 30 | Mixed Ether/Ester Plasticizer | Safic-Alcan |
| Fillers | | |
| Spheron [®] SO N550 | Carbon Black | Cabot Corporation |
| Curatives | | |
| Rubber chem. Diak [™] #1 | Hexamethylene Diamine Carbamate | DuPont |
| Vulcofac [®] HDC MB 75 | Hexamethylene Diamine Carbamate | Safic-Alcan |
| Ekaland DOTG/C | Di-ortho-tolyl Guanidine | MLPC International |
| Rhenogran DPG 80% | Diphenyl Guanidine | Rhein Chemie |
| Vulcofac [®] ACT 55 | Animated Derivatives | Safic-Alcan |

Materials Used in Formulations — General Composition and Supplier

Visit us at vamac.dupont.com

Contact DuPont at the following regional locations:

| North America | Latin America | Europe, Middle East, Africa |
|----------------------|----------------|-----------------------------|
| +800-222-8377 | +0800 17 17 15 | +41 22 717 51 11 |
| Greater China | ASEAN | Japan |
| +86-400-8851-888 | +65-6586-3688 | +81-3-5521-8484 |

The information set forth herein is furnished free of charge and is based on technical data that DuPont believes to be reliable and falls within the normal range of properties. It is intended for use by persons having technical skill, at their own discretion and risk. This data should not be used to establish specification limits nor used alone as the basis of design. Handling precaution information is given with the understanding that those using it will satisfy themselves that their particular conditions of use present no health or safety hazards. Since conditions of product use and disposal are outside our control, we make no warranties, express or implied, and assume no liability in connection with any use of this information. As with any product, evaluation under end-use conditions prior to specification is essential. Nothing herein is to be taken as a license to operate or a recommendation to infringe on patents.

Caution: Do not use in medical applications involving permanent implantation in the human body. For other medical applications, discuss with your DuPont customer service representative and read Medical Caution Statement H-50103-3.

Copyright © 2010 DuPont. The DuPont Oval Logo, DuPont[™], The miracles of science[™], and Vamac[®] are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or its affiliates. All rights reserved.

(01/07) Reference No. VME-A10623-00-C0710

